Zacks Investment Research
15 Jan 2026, 00:15 UTC · 38w ago
Verdict
Headline takes no side. We score DNA +0.20 across four claims — slightly bullish.
+0.20slightly bullish
More positive than 53% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Ginkgo Bioworks' upcoming quarterly revenue is projected at $37 million, representing a 15.62% year-over-year decline.
So whatA significant double-digit revenue decline signals contracting business operations, which is a direct negative for the company's valuation and risk appetite.
More negative than 95% of claims this week
Ginkgo Bioworks shares gained 16.47% over the past month, significantly outpacing the S&P 500's 2.06% gain.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 78% of claims this week
The full-year consensus estimate calls for earnings of -$5.94 per share, reflecting a 42.66% year-over-year improvement.
So whatWhile still a loss, a sharp projected improvement in EPS indicates better cost control or a path toward profitability, providing a modest positive signal.
More positive than 65% of claims this week
Ginkgo Bioworks holds a Zacks Rank of #3 (Hold) with no change in the consensus EPS estimate over the past month.
Near neutral — 99% of claims this week are stronger
Which stocks this story touches
More positive than 53% of ticker scores this week
The stock price rose 2.39% in the latest session and 16.47% over the past month, though earnings projections remain negative.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
1h ago
+16.4%
Price agrees with the score
$11.47 vs $9.85 close before publication (Jan 14) · not market-adjusted
DNA chart →
